Contact
searchSearch
HMP Global
Login
Breast Cancer

Dr Loprinzi Reviews Hot Flash Treatment Strategies in BC, Part I

03/14/2022

Charles Loprinzi, MD, Mayo Clinic, highlights some non-estrogenic approaches to hot flash management for patients with breast cancer, presented at the 39th Annual Miami Breast Cancer Conference.

Recent News

FDA Approval
FDA Approves Penpulimab for Patients With Non-Keratinizing Nasopharyngeal Carcinoma
04/24/2025
Stephanie Holland
On April 23, 2025, the FDA has approved penpulimab plus chemotherapy for patients with metastatic non-keratinizing nasopharyngeal carcinoma.
On April 23, 2025, the FDA has approved penpulimab plus chemotherapy for patients with metastatic non-keratinizing nasopharyngeal carcinoma.
On April 23, 2025, the FDA has...
04/24/2025
Oncology
News
Lenvatinib-Based Regimens Demonstrate Efficacy, Safety Among Pre-Treated Patients With Metastatic Renal Cell Carcinoma
04/24/2025
Stephanie Holland
According to retrospective results from the LENVA-LAT study, treatment with lenvatinib-based regimens demonstrated efficacy and safety among pre-treated patients with metastatic renal cell carcinoma.
According to retrospective results from the LENVA-LAT study, treatment with lenvatinib-based regimens demonstrated efficacy and safety among pre-treated patients with metastatic renal cell carcinoma.
According to retrospective...
04/24/2025
Oncology
News
Palbociclib Plus Endocrine Therapy May Prolong Progression-Free Survival for Premenopausal Patients With HR-Positive, HER2-Negative Breast Cancer
04/23/2025
Stephanie Holland
According to extended follow-up results from the phase 2 Young-PEARL trial, palbociclib plus exemestane and ovarian function suppression prolonged progression-free survival among premenopausal patients with HR-positive, HER2-negative...
According to extended follow-up results from the phase 2 Young-PEARL trial, palbociclib plus exemestane and ovarian function suppression prolonged progression-free survival among premenopausal patients with HR-positive, HER2-negative...
According to extended follow-up...
04/23/2025
Oncology
News
Trastuzumab Rezetecan for Patients With HER2-Mutated Non-Small Cell Lung Cancer
04/22/2025
Stephanie Holland
According to results from the phase 2 HORIZON-Lung trial, trastuzumab rezetecan demonstrated promise among patients with HER2-mutated non-small cell lung cancer.
According to results from the phase 2 HORIZON-Lung trial, trastuzumab rezetecan demonstrated promise among patients with HER2-mutated non-small cell lung cancer.
According to results from the...
04/22/2025
Oncology
News
Temozolomide as Potential Second-Line Option for Patients With Small Cell Lung Cancer
04/21/2025
Stephanie Holland
According to results from a retrospective analysis of a real-world cohort, temozolomide showed potential as a second-line option for patients with small cell lung cancer.
According to results from a retrospective analysis of a real-world cohort, temozolomide showed potential as a second-line option for patients with small cell lung cancer.
According to results from a...
04/21/2025
Oncology
News
Adding Pembrolizumab to Docetaxel Does Not Improve Survival Outcomes for Metastatic Castration-Resistant Prostate Cancer
04/21/2025
Stephanie Holland
According to results from the phase 3 KEYNOTE-921 trial, the addition of pembrolizumab to docetaxel did not significantly improve survival outcomes among previously treated patients with metastatic castration-resistant prostate cancer.
According to results from the phase 3 KEYNOTE-921 trial, the addition of pembrolizumab to docetaxel did not significantly improve survival outcomes among previously treated patients with metastatic castration-resistant prostate cancer.
According to results from the...
04/21/2025
Oncology
News
Sacituzumab Govitecan Fails to Significantly Improve Survival in Advanced Urothelial Carcinoma
04/17/2025
Stephanie Holland
According to final analysis results from the phase 3 TROPICS-04 trial, sacituzumab govitecan did not significantly improve survival among previously treated patients with advanced urothelial carcinoma.
According to final analysis results from the phase 3 TROPICS-04 trial, sacituzumab govitecan did not significantly improve survival among previously treated patients with advanced urothelial carcinoma.
According to final analysis...
04/17/2025
Oncology
News
Rituximab Plus Lenalidomide Shows Durable Responses as Frontline Treatment for Patients With Follicular Lymphoma
04/16/2025
Emily Estrada
Rituximab plus lenalidomide demonstrates long-lasting responses and improved outcomes as first-line therapy for follicular lymphoma, according to a phase 2 trial.
Rituximab plus lenalidomide demonstrates long-lasting responses and improved outcomes as first-line therapy for follicular lymphoma, according to a phase 2 trial.
Rituximab plus lenalidomide...
04/16/2025
Oncology
News
Tegafur-Uracil Maintenance Did Not Improve Survival for Patients With Locally Advanced Cervical Cancer
04/15/2025
Stephanie Holland
According to results from the phase 3 GOTIC-002 trial, low-dose tegafur-uracil maintenance therapy did not improve survival among patients with locally advanced cervical cancer.
According to results from the phase 3 GOTIC-002 trial, low-dose tegafur-uracil maintenance therapy did not improve survival among patients with locally advanced cervical cancer.
According to results from the...
04/15/2025
Oncology
News
First-Line Durvalumab Plus Platinum-Etoposide for Patients With Extensive-Stage Small Cell Lung Cancer
04/14/2025
Stephanie Holland
According to final efficacy and safety results from the phase 3b LUMINANCE trial, first-line durvalumab plus platinum-etoposide demonstrated promise among patients with extensive-stage small cell lung cancer.
According to final efficacy and safety results from the phase 3b LUMINANCE trial, first-line durvalumab plus platinum-etoposide demonstrated promise among patients with extensive-stage small cell lung cancer.
According to final efficacy and...
04/14/2025
Oncology

Specialties

Events

Year Round Education

HMP Global Products

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2025 HMP Global. All Rights Reserved.
Cookie Policy Privacy Policy Term of Use